share_log

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target

Needham重申對Recursion Pharmaceuticals的買入評級,維持11美元的目標股價
Benzinga ·  12/11 21:26  · 評級/大行評級

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $11 price target.

Needham的分析師Gil Blum重申Recursion Pharmaceuticals(納斯達克:RXRX)的買入評級,並維持11美元的目標價格。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論